Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Synlogic’s mission is to utilize its Synthetic Biotic™ medicines to treat metabolic, immunologic, and inflammatory diseases.

The vision of the company is to create a new class of therapies that enable doctors to manage complex diseases with great efficiency and accuracy. This would allow patients to live healthier and longer lives.

Synlogic has won numerous awards, including the Frost & Sullivan Technology Innovation Award, the Cancer Research Institute Immunotherapy Award, BioInnovation Quebec-Insp? Award, Pitch @ Palace, and the Red Herring Top 100 North America Award.